Reductase activity of aldehyde oxidase toward the carcinogen N-hydroxy-2-acetylaminofluorene and the related hydroxamic acids.
Liver aldehyde oxidase (EC 1.2.3.1) was capable of reducing N-arylacetohydroxamic acids, N-hydroxy-2-acetyl-aminofluorene, N-hydroxy-4-acetylaminobiphenyl and N-hydroxyphenacetin, to the corresponding amides in the presence of an electron donor of the enzyme under anaerobic conditions. When supplemented with an electron donor of the enzyme, a significant reduction of N-hydroxy-2-acetylaminofluorene occurred, which was sensitive to an inhibitor of the enzyme. These observations were made with cytosolic fractions prepared from the livers of rabbits, guinea pigs, rats and mice.
Kitamura
S
S
Institute of Pharmaceutical Science, Hiroshima University School of Medicine, Japan.
Sugihara
K
K
Tatsumi
K
K
D042931:Aldehyde Oxidase; D000445:Aldehyde Oxidoreductases / Q000037:antagonists & inhibitors / Q000378:metabolism*; D000447:Aldehydes; D000611:Aminobiphenyl Compounds / Q000378:metabolism*; D000818:Animals; D002273:Carcinogens / Q000378:metabolism; D006168:Guinea Pigs; D006877:Hydroxamic Acids / Q000378:metabolism*; D006881:Hydroxyacetylaminofluorene / Q000378:metabolism*; D008099:Liver / Q000201:enzymology* / Q000378:metabolism; D051379:Mice; D010084:Oxidation-Reduction; D010615:Phenacetin / Q000031:analogs & derivatives* / Q000378:metabolism; D011817:Rabbits; D051381:Rats; D014812:Vitamin K / Q000494:pharmacology
D000447:Aldehydes; D000611:Aminobiphenyl Compounds; D002273:Carcinogens; D006877:Hydroxamic Acids; D014812:Vitamin K; C008068:N-hydroxyphenacetin; C001365:N-hydroxy-4-acetylaminobiphenyl; D006881:Hydroxyacetylaminofluorene; D000445:Aldehyde Oxidoreductases; D042931:Aldehyde Oxidase; D010615:Phenacetin; C018475:butyraldehyde